Korro Bio, Inc.

Korro Bio, Inc. announced the grant of non-statutory stock options to seven newly hired employees. Four employees received options for an aggregate of 6,000 shares at an exercise price of $10.59 per share, while three employees received options for an aggregate of 17,000 shares at $14.72 per share. These options have a ten-year term and vest over four years, with 25% vesting on the first anniversary and the remainder in monthly installments. The grants were approved by Korro's independent Compensation Committee under the 2026 Inducement Plan as an inducement for employment.

Korro Bio, Inc. announced the addition of KRRO-111 to its pipeline as a development candidate for the potential treatment of Alpha-1 Antitrypsin Deficiency (AATD). Preclinical studies demonstrated that KRRO-111 achieved over 90% editing of the SERPINA1 transcript in vivo, translating to approximately 90% repaired functional AAT protein in plasma in a mouse model. The therapeutic also nearly eliminated active Z-protein production and progressively cleared pre-existing aggregates, positioning it as a potential best-in-class subcutaneous treatment. The company is well-capitalized with a cash runway into the second half of 2028.

Korro Bio announced the addition of KRRO-111 to its pipeline for the potential treatment of Alpha-1 Antitrypsin Deficiency (AATD). Preclinical data showed KRRO-111 achieved over 90% editing of the SERPINA1 transcript, resulting in approximately 90% repaired functional AAT protein in plasma and a near elimination of active Z-protein production in a mouse model. This positions KRRO-111 as a potential best-in-class candidate, leveraging the company's OPERA platform to address the root cause of AATD. Korro Bio is well-capitalized to advance KRRO-111 and KRRO-121 into clinical trials.

Korro Bio, Inc. announced the grant of a non-statutory stock option to one newly hired employee. The option allows the purchase of 3,000 shares of common stock at an exercise price of $11.20 per share. This grant, effective May 13, 2026, has a ten-year term and vests over four years, with 25% vesting on the first anniversary and the remainder monthly. It was approved by the Compensation Committee as an inducement for employment.

Korro Bio reported a net loss of $19.6 million for Q1 2026, an improvement from $23.4 million in Q1 2025, while collaboration revenue dropped to zero. The company significantly bolstered its liquidity by raising $88.2 million through a private placement and an at-the-market equity program. This capital infusion increased cash, cash equivalents, and marketable securities to $157.1 million, extending its cash runway for at least 12 months, despite the ongoing accumulated deficit and a paused collaboration with Novo Nordisk.

Korro Bio reported its first quarter 2026 financial results, including a net loss of $19.6 million. The company successfully executed an oversubscribed $85 million private placement, extending its cash runway into the second half of 2028. Key pipeline advancements include KRRO-121 remaining on track for regulatory filing in H2 2026 and a GalNAc-conjugated oligonucleotide for AATD achieving over 90% in vivo RNA editing, with a development candidate expected in Q2 2026.

Korro Bio, Inc. announced upcoming oral and poster presentations highlighting data from its oligonucleotide delivery based RNA editing technology (OPERA®) at four scientific conferences in April and May 2026. The presentations will cover preclinical data for KRRO-121 in hyperammonemia, RNA editing for Alpha-1 Antitrypsin Deficiency models, and advancements in the OPERA® platform capabilities. These presentations underscore the company's progress in developing genetic medicines for various diseases.

Korro Bio, Inc. announced the grant of a non-statutory stock option to a newly hired employee. The option allows the purchase of 15,000 shares of common stock at an exercise price of $13.46 per share, matching the closing price on April 8, 2026. This grant, approved by independent directors under the 2026 Inducement Plan, vests over four years and serves as an inducement for the employee's acceptance of employment.